Why did the FDA approve abemaciclib for early breast cancer based on Ki-67 data?
In the Q&A and panel discussion from Session 4, Dr Vidal asks Dr Tolaney why the FDA approved abemaciclib for early breast cancer based only on Ki-67 data, as this measure alone is not predictive of abemaciclib benefit.